- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Glaukos Corp (GKOS)
Track the Glaukos Corp share price today and view real-time GKOS share price data, including charts, technicals, and key financials. View the GKOS premarket stock price ahead of the market session or assess the after hours quote. Explore GKOS stock price movements, trading volume, and market activity across the NYSE exchange.
What Is the Glaukos Corp Stock Price Today?
The Glaukos Corp stock price today is 166.72.
What Is the Stock Symbol for Glaukos Corp?
The stock symbol for Glaukos Corp is ""GKOS.""
What Stock Exchange Does Glaukos Corp Trade On?
Glaukos Corp is listed and trades on the NYSE stock exchange.
Is Glaukos Corp a Good Stock to Buy?
Determining whether Glaukos Corp or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GKOS quote. (ISIN: US3773221029)
What Is the Glaukos Corp Stock Price Today?
The Glaukos Corp stock price today is 166.72.
What Is the Stock Symbol for Glaukos Corp?
The stock symbol for Glaukos Corp is ""GKOS.""
What Stock Exchange Does Glaukos Corp Trade On?
Glaukos Corp is listed and trades on the NYSE stock exchange.
Is Glaukos Corp a Good Stock to Buy?
Determining whether Glaukos Corp or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GKOS quote. (ISIN: US3773221029)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
165.37
171.55
52 wk Range
73.16
184.00
GKOS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
165.37171.55
52 wk Range
73.16184.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GKOS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
193.62
Upside
+16.13%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
Glaukos Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Glaukos Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Glaukos Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
13 Buy
1 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 193.62
(+16.13% Upside)
Glaukos Corp Earnings Call Summary for Q2/2026
- Glaukos Q2 revenue hit $185.6M, up 50% YoY, beating estimates by $34.5M; EPS loss of 14¢ vs. 21¢ forecast; shares surged 8.87% after-hours to $176.
- Full-year 2026 guidance raised to $680M-$700M from $620M-$635M; iDose TR expected to generate $275M-$285M with U.S. glaucoma growth near 50%.
- iDose TR drove growth with ~$74M in Q2 sales; Epioxa added $11M in first full quarter; gross margin improved to 85%, up 90 basis points sequentially.
- Management sees clear path to profitability while maintaining $600M operating expense guidance; Q3 may see seasonal softness before Q4 acceleration.
- Epioxa net pricing starts at ~$60K per treatment; site-of-care network covers 85% of U.S., targeting 95%; J-code transition may create near-term volatility.
Last Updated: 30/07/2026, 07:38 am
Read Full TranscriptEarnings
Latest Release
29/07/2026
EPS / Forecast
-0.14 / -0.21
Revenue / Forecast
185.6M / 151.13M
Compare GKOS to Peers and Sector
Metrics to compare | GKOS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGKOSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −52.3x | −11.5x | −0.4x | |
PEG Ratio | 0.54 | −0.22 | 0.00 | |
Price/Book | 14.4x | 4.0x | 2.6x | |
Price / LTM Sales | 16.0x | 4.0x | 3.0x | |
Upside (Analyst Target) | 15.8% | 65.5% | 56.0% | |
Fair Value Upside | Unlock | −14.9% | 9.1% | Unlock |
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Glaukos Corp (GKOS) Stock Price Today?
The Glaukos Corp stock price today is 166.72 USD.
What Stock Exchange Does Glaukos Corp Trade On?
Glaukos Corp is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Glaukos Corp?
The stock symbol for Glaukos Corp is "GKOS."
What Is the Glaukos Corp Market Cap?
As of today, Glaukos Corp market cap is 9.83B USD.
What Is Glaukos Corp's Earnings Per Share (TTM)?
The Glaukos Corp EPS (TTM) is -3.25.
When Is the Next Glaukos Corp Earnings Date?
Glaukos Corp will release its next earnings report on 04/11/2026.
From a Technical Analysis Perspective, Is GKOS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Glaukos Corp Stock Split?
Glaukos Corp has split 0 times.
How Many Employees Does Glaukos Corp Have?
Glaukos Corp has 1094 employees.
What is the current trading status of Glaukos Corp (GKOS)?
As of 03/08/2026, Glaukos Corp (GKOS) is trading at a price of 166.72 USD, with a previous close of 166.72 USD. The stock has fluctuated within a day range of 165.37 USD to 171.55 USD, while its 52-week range spans from 73.16 USD to 184.00 USD.
What Is Glaukos Corp (GKOS) Price Target According to Analysts?
The average 12-month price target for Glaukos Corp is 193.62 USD, with a high estimate of 215 USD and a low estimate of 172 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +16.13% Upside potential.
What Is the GKOS After Hours Price?
GKOS's last after hours stock price is 172.31 USD, the stock has decreased by 5.59, or 3.35%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.